logo

For the Inventor, By the Inventor

Prague, Czechia

Zentiva K.s.


USPTO Granted Patents = 20

% Expired Patents = 35.0


Forward Citations = 5

Loading Chart...
Loading Chart...

45 inventors (with patents filed for the assignee):

goldMedal Jindrich Richter (6 out of 9 patents)

silverMedal Ludek Ridvan (6 out of 7 patents)

bronzeMedal Ondrej Dammer (4 out of 5 patents)

4.  Josef Jirman (4 out of 7 patents)

5.  Lukas Placek (4 out of 4 patents)

6.  Kamal Jarrah (3 out of 3 patents)

7.  Tomas Pekarek (3 out of 3 patents)

8.  Petr Lustig (3 out of 4 patents)

9.  Monika Zatopkova (3 out of 3 patents)

10.  Josef Hajicek (3 out of 4 patents)

11.  Karel Ulbrich (2 out of 5 patents)

12.  Stanislav Radl (2 out of 2 patents)

13.  Lukas Krejcik (2 out of 2 patents)

14.  Tomas Etrych (2 out of 3 patents)

15.  Blanka Rihova (2 out of 4 patents)


20 patents:

1. 10532981 - Crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate salts and methods of preparation thereof (2020-01-14),
2. 10457671 - Crystalline form of Canagliflozin and a method of its preparation (2019-10-29),
3. 10125122 - Method for preparing methyl (Z)-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene)oxindole-6-carboxylate (intedanib, nintedanib) (2018-11-13),
4. 9920021 - Method of preparing vortioxetine (2018-03-20),
5. 9862723 - Stable polymorph of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-anime with L-tartaric acid (2018-01-09),
6. 8927771 - Pharmaceutically acceptable cocrystals of N-[2-(7-methoxyl-1-naphtyl)ethyl]acetamide and methods of their preparation (2015-01-06),
7. 8779005 - Salts of desvenlafaxine and a method of their preparation (2014-07-15),
8. 8603990 - Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation (2013-12-10),
9. 8394962 - Method for the preparation of dabigatran and its intermediates (2013-03-12),
10. 8394961 - Method for the preparation of dabigatran (2013-03-12),
11. 8207356 - Method for the preparation of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) (2012-06-26),
12. 8143417 - Method for the preparation of zolmitriptan (2012-03-27),
13. 8071791 - [object Object] (2011-12-06),
14. 8034942 - Process for the preparation of solifenacin (2011-10-11),
15. 8034807 - Salts of bazedoxifene (2011-10-11),
Company Overview
Zentiva K.s. is a prominent pharmaceutical company based in Prague, Czech Republic, specializing in the development and manufacturing of generic medicines. The organization focuses on providing high-quality, affordable healthcare solutions across various therapeutic areas, including cardiovascular, central nervous system, and infectious diseases. Zentiva is committed to innovation in drug formulation and delivery, ensuring accessibility to essential medications for patients in Europe and beyond.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

20 Patents

#10 in Prague

#22 in Czechia

#31,264 in the World

Prague, CZ
Prague, Czechia

Zentiva K.s.

Forward Citations = 5

45 inventors:

goldMedal Jindrich Richter (6 out of 9 patents)

silverMedal Ludek Ridvan (6 out of 7 patents)

bronzeMedal Ondrej Dammer (4 out of 5 patents)

4.  Josef Jirman (4 out of 7 patents)

5.  Lukas Placek (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zentiva K.s.. Retrieved from https://idiyas.com/company/zentiva-k-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…